San Francisco, CA (UroToday.com) — Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, announced that new data from two oncology programs have been selected for oral presentations at the European Society for Medical Oncology (ESMO) 2019 Congress to be held September 27-October 1, in Barcelona, Spain.
The late-breaking abstract (#LBA54) titled, “ENTRATA: Randomized, double-blind, phase 2 study of telaglenastat (CB-839) + everolimus vs. placebo + everolimus in patients with advanced/metastatic renal cell carcinoma (RCC),” has been selected for oral presentation as part of a session titled, “Proffered Paper 1-Genitourinary tumors, non-prostate” on September 28, 2019, at 8:30 a.m. CET in Barcelona Auditorium (Hall 2). The oral presentation will be led by Chung-Han Lee of the Memorial Sloan Kettering Cancer Center, New York, NY.
The oral abstract (#440O) titled, “Phase 1 study of the arginase inhibitor INCB001158 (1158) alone and in combination with pembrolizumab in patients with advanced/metastatic solid tumors,” has been accepted for oral presentation as part of a session titled, “Proffered Paper – Developmental therapeutics,” on September 29, 2019, at 4:30 p.m. CET in the Malaga Auditorium (Hall 5). The oral presentation will be led by Aung Naing, M.D., FACP, Associate Professor, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
“We look forward to presenting data from the ENTRATA trial, for which positive topline results were announced earlier this year, as well as new data from our clinical program partnered with Incyte that is evaluating the arginase inhibitor INCB001158 in solid tumors,” said Susan Molineaux, Ph.D., president and chief executive officer at Calithera. “We remain committed to advancing our robust pipeline, including our lead compound telaglenastat for which the registrational CANTATA trial in RCC is underway and expected to readout in the second half of 2020.”
Source: Calithera Biosciences, Inc. 2019. “Calithera Biosciences to Present New Data on Two Oncology Programs at ESMO Congress 2019”. GlobeNewswire News Room. https://www.globenewswire.com/news-release/2019/09/03/1910085/0/en/Calithera-Biosciences-to-Present-New-Data-on-Two-Oncology-Programs-at-ESMO-Congress-2019.html.
Clinical Trial Information: NCT03163667:
ENTRATA: CB-839 With Everolimus vs. Placebo With Everolimus in Patients With RCC
Clinical Trial Information: NCT03428217:
CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma